Biotech | October 07, 2025
Lonza expands cell and gene therapy portfolio
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
IND application for EB-003 expected in early 2026
Subscribe To Our Newsletter & Stay Updated
